

Exhibit A

```

<!--StartFragment-->RESULT 9
AAB50913
ID   AAB50913 standard; protein; 258 AA.
XX
AC   AAB50913;
XX
DT   15-JUN-2007 (revised)
DT   21-MAR-2001 (first entry)
XX
DE   Human PRO861 protein.
XX
KW   Human; PRO; antiinflammatory; dermatological; antiarthritic;
KW   antirheumatic; cardiant; antianaemic; immunosuppressive; antithyroid;
KW   antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;
KW   antiallergic; antiasthmatic; immune related disorder;
KW   hepatobiliary disease; autoimmune disease; allergy; BOND_PC;
KW   insulin-like growth factor binding protein 4;
KW   insulin-like growth factor-binding protein 4;
KW   insulin-like growth factor binding protein 4 [Homo sapiens]; IGFBP4;
KW   IGF4; insulin-like growth factor binding protein 4 precursor;
KW   IGF-binding protein 4;
KW   insulin-like growth factor binding protein 4 precursor [Homo sapiens];
KW   IGF-4; IGFBP-4; IGF-4; IGFBP-4;
KW   insulin-like growth factor binding protein 4, isoform CRA_a; IGF-BP 4;
KW   insulin-like growth factor binding protein 4 [synthetic construct];
KW   G01501; G01558; G05520; G05576; G06259; G07165; G08283.
XX
OS   Homo sapiens.
XX
PN   WC200073452-A2.
XX
FD   07-DEC-2000.
XX
FF   02-JUN-2000; 2000WO-US015264.
XX
PR   02-JUN-1999; 99WO-US012252.
PR   20-JUL-1999; 99US-0144732F.
PR   20-JUL-1999; 99US-0144758F.
PR   28-JUL-1999; 99US-0146222P.
PR   01-SEP-1999; 99WO-US020111.
PR   15-SEP-1999; 99WO-US021090.
PR   15-SEP-1999; 99WO-US021547.
PR   29-OCT-1999; 99US-0162506P.
PR   30-NOV-1999; 99WO-US028313.
PR   01-DEC-1999; 99WO-US028634.
PR   02-DEC-1999; 99WO-US028551.
PR   02-DEC-1999; 99WO-US028565.
PR   09-DEC-1999; 99US-0170262P.
PR   20-DEC-1999; 99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005061.
PR   02-MAR-2000; 2000WO-US005841.
PR   03-MAR-2000; 2000US-0187202P.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
XX
FA   (GETH ) GENENTECH INC.
XX
FI   Ashkenazi AJ, Baker KP, Chan B, Goddard A, Godowski PJ;
PI   Gurney AL, Hebert C, Henzel W, Kabakoff RC, Shelton DL, Tumas D;
PI   Watanabe CK, Wood WI;
XX
DR   WPI; 2001-025253/03.
DR   N-PSDB; AAC91472.
DR   PC:NCBI; gi62243290.

```

DR PC:SWISSPROT; P22692.
 DR PC:BIOS; 308505.
 XX
 PT Thirty three nucleic acids encoding PRO polypeptides which are useful in
 PT the diagnosis and treatment of immune related disorders, e.g. systemic
 PT lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis
 PT and diabetes mellitus.
 XX
 PS Claim 58; Fig 24; 218pp; English.
 XX
 CC The present sequence is one of thirty three novel PRO polypeptides. The
 CC PRO polypeptides, anti-PRO antibodies, agonists and antagonists are
 CC useful for treating and diagnosing immune related disorders such as
 CC systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
 CC juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,
 CC idiopathic inflammatory myopathies, Sjogren's syndrome, systemic
 CC vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
 CC thrombocytopaenia, thyroiditis, diabetes mellitus, immune-mediated renal
 CC disease, demyelinating diseases of the central and peripheral nervous
 CC systems (such as multiple sclerosis, idiopathic demyelinating
 CC polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory
 CC demyelinating polyneuropathy), hepatobiliary diseases (such as
 CC infectious, autoimmune chronic active hepatitis, primary biliary
 CC cirrhosis, granulomatous hepatitis and sclerosing cholangitis),
 CC inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's
 CC disease, autoimmune or immune-mediated skin diseases (such as bullous
 CC skin diseases, erythema multiforme, contact dermatitis, psoriasis),
 CC allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,
 CC food hypersensitivity and urticaria), immunological diseases of the lung
 CC (such as eosinophilic pneumonia, idiopathic pulmonary fibrosis and
 CC hypersensitivity pneumonitis), transplantation associated diseases
 CC including graft rejection and graft-versus-host diseases
 CC
 CC Revised record issued on 15-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 258 AA;

Query Match 100.0%; Score 1336; DB 4; Length 258;
 Best Local Similarity 100.0%; Pred. No. 9.4e-115;
 Matches 237; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 DEATHCPPCSEELARCRPPVGCCELVREPCCGCCATCALGLMPCGVYTPRCGSGRLCY 60
 Db 22 DEATHCPPCSEELARCRPPVGCCELVREPCCGCCATCALGLMPCGVYTPRCGSGRLCY 81

Qy 61 PPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDEGHPNNSFSPCSAHDRCCLQK 120
 Db 82 PPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDEGHPNNSFSPCSAHDRCCLQK 141

Qy 121 HFAKIRDRSTGGGKMKVNGAPREDARVPVQSGSCQSELHRALERLAASQSRTHEDLYIPI 180
 Db 142 HFAKIRDRSTGGGKMKVNGAPREDARVPVQSGSCQSELHRALERLAASQSRTHEDLYIPI 201

Qy 181 PNCDRNGNFHPKQCHPALDQGRGKCWCVDRTGVKLPGLGLEPKGELDKHQLDSPRE 237
 Db 202 PNCDRNGNFHPKQCHPALDQGRGKCWCVDRTGVKLPGLGLEPKGELDKHQLDSPRE 258

<!--EndFragment-->